HIMS · Hims & Hers Health, Inc.
Price
Snapshot
50 fields · last close| Market Cap | $6.22B |
| P/E | 48.46 |
| Float | 213.0M |
| Beta | 2.58 |
| Volatility 30D | 65.0% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Mid cap |
| Macro sensitivity | Very High |
| Clavix score | 40.0 |
| Price | 23.48 |
| Change | −11.93% |
| Prev Close | 26.66 |
| Open | 25.92 |
| Day Low | 25.92 |
| Day High | 28.66 |
| Avg Vol | 9 |
| Avg $ Vol | $230.4M |
| 52W High | 48.34 |
| 52W Low | 13.74 |
| 52W Pos | 28.2% |
| From High | −51.43% |
| From Low | +70.89% |
| Max DD 1Y | −66.80% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −17.28% |
| SMA 50 | −18.07% |
| SMA 200 | −12.88% |
| RSI (14) | 43.6 |
| Vol 90D | 80.2% |
| Vol 1Y | 86.9% |
| 1Y Range | 14–48 |
| Daily bars | 549 |
| Perf Week | −9.07% |
| Perf Month | −9.54% |
| Perf Quarter | −10.11% |
| Perf Half Y | −0.82% |
| Perf Year | −39.94% |
| Perf YTD | −29.72% |
| Prev Day | −11.93% |
| Clavix | D- |
| Debt / Eq | 1.80 |
| Curr Ratio | 1.90 |
| Int Cover | — |
| FCF Margin | 12.8% |
| Rev Growth | +59.0% |
| Profit | Profitable |
| Leverage | High |
| Sector rank | 48 / 49 |
What HIMS does
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally.
The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers.
Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services.
Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health.
The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.
Clavix risk grade
regraded every trading dayHIMS grades D-, 40.0 of 100. Steadiest on Sector Resilience (72), most exposed on Macro Resilience (22, weak). 1 of the 4 weighted dimensions sit above the Health Care median. Ranks 48 of 49 in Health Care by Clavix score.
How rough the ride is
| HIMS | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 2.58 | 0.79 |
| 30-day realized volatilityannualized, from daily closes | 65.0% | 36.1% |
| Max drawdown, past yearworst peak-to-trough fall | −66.8% | — |
| Typical daily movemedian absolute daily change | 3.15% | — |
| Days beyond ±3%of the last 252 sessions | 134 (53%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| HIMS | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 2.58 | 0.79 |
| Macro sensitivityrate, dollar and credit exposure bucket | Very High | Moderate 51% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| HIMS | |
|---|---|
| 1 week | −9.1% |
| 1 month | −9.5% |
| Year to date | −29.7% |
| 1 year | −39.9% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| HIMS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 26 Oct |
| Average score0 most bearish, 100 most bullish | 24 |
| Bullish · bearisharticles above 60 · below 40 | 0 · 29 |
| Directionarticles whose tone is improving vs worsening | 0 ↑ 29 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| HIMS | |
|---|---|
| Revenue growthyear over year | +59.0% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openRosen Law Firm says Nov. 2, 2026, is the deadline to seek lead plaintiff status, or serve as the main representative for a group of investors, in a securities fraud lawsuit involving Hims & Hers Health. It says investors who bought HIMS securities from Aug. 4, 2025, through July 29, 2026, may be entitled to compensation through a contingency fee arrangement with no upfront costs.
Rosen Law Firm said investors who bought Hims & Hers Health (NYSE: HIMS) securities from August 4, 2025 through July 29, 2026 have until November 2, 2026 to seek lead plaintiff counsel in a securities class action. It said eligible investors may seek compensation through a contingency-fee arrangement without paying upfront legal fees, but the article provides no details about the allegations or the case’s merits.
A federal securities class action, a lawsuit that groups claims from multiple investors, has been filed against Hims & Hers Health. The deadline for investors seeking to serve as the group’s lead plaintiff is November 2, 2026, and Faruqi & Faruqi said it is investigating potential claims.
Kessler Topaz Meltzer & Check announced a class-action lawsuit seeking recovery for investors who bought Hims & Hers Health securities between August 4, 2025 and July 29, 2026. The firm listed November 2, 2026 as the deadline to contact it about the case.
Rosen Law Firm reminded investors who bought HIMS securities between August 4, 2025 and July 29, 2026 that November 2, 2026 is the deadline to seek lead plaintiff status in a securities class action. It urged investors with losses exceeding $100,000 to secure legal counsel before the deadline.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| RDNT | RadNet, Inc. | B | $6.32B | — | 1.41 | Compare |
| CRVL | CorVel Corporation | B+ | $4.41B | 36.20 | 1.07 | Compare |
| HNGE | Hinge Health, Inc. | B- | $9.75B | 86.44 | 1.57 | Compare |
| HSIC | Henry Schein, Inc. | A- | $9.83B | 24.29 | 0.85 | Compare |
| UHS | Universal Health Services, Inc. | A- | $10.47B | 7.56 | 1.10 | Compare |
| PODD | Insulet Corporation | B- | $11.44B | 28.61 | 1.08 | Compare |
| GMED | Globus Medical, Inc. | B+ | $11.69B | 19.96 | 0.93 | Compare |
| ALGN | Align Technology, Inc. | B | $11.71B | 27.75 | 1.72 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.